Allarity Therapeutics (NASDAQ:ALLR) Issues Quarterly Earnings Results, Misses Estimates By $0.18 EPS

Allarity Therapeutics (NASDAQ:ALLR) posted its earnings results on Friday. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.18), FiscalAI reports. The company had revenue of $0.01 million during the quarter. Allarity Therapeutics updated its FY 2026 guidance to -0.760–0.730 EPS and its Q4 2026 guidance to 0.010-0.040 EPS.

Allarity Therapeutics Trading Up 4.4%

Shares of Allarity Therapeutics stock traded up $0.04 on Friday, hitting $0.95. 279,178 shares of the company traded hands, compared to its average volume of 151,355. Allarity Therapeutics has a 12-month low of $0.77 and a 12-month high of $1.84. The company has a market cap of $15.17 million, a P/E ratio of -1.22 and a beta of 0.57. The firm’s 50-day simple moving average is $1.02 and its 200 day simple moving average is $1.21.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Allarity Therapeutics in a research report on Thursday, October 15th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $10.25.

Allarity Therapeutics Company Profile

Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage biotechnology company focused on developing personalized treatments for cancer. The company uses its Drug Response Predictor (DRP) technology to analyze patient and tumor characteristics and identify individuals who may be more likely to respond to specific drug candidates. Allarity’s development programs have included stenoparib, also known as 2X-121, an orally administered PARP inhibitor being investigated for potential use in oncology.